Published in Am J Trop Med Hyg on March 01, 1998
Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother (2000) 2.68
Molecular epidemiology of malaria. Clin Microbiol Rev (2007) 1.53
Hitchhiking and selective sweeps of Plasmodium falciparum sulfadoxine and pyrimethamine resistance alleles in a population from central Africa. Antimicrob Agents Chemother (2008) 1.34
Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother (1998) 1.28
Molecular correlates of high-level antifolate resistance in Rwandan children with Plasmodium falciparum malaria. Antimicrob Agents Chemother (2009) 1.17
High prevalence of mutation in the Plasmodium falciparum dhfr and dhps genes in field isolates from Sabah, Northern Borneo. Malar J (2013) 0.81
Prevalence of the dhfr and dhps Mutations among Pregnant Women in Rural Burkina Faso Five Years after the Introduction of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine. PLoS One (2015) 0.78
Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 3.40
Nitric oxide in cerebral malaria. J Infect Dis (1994) 1.64
Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans R Soc Trop Med Hyg (2000) 1.51
High levels of circulating IL-10 in human malaria. Clin Exp Immunol (1994) 1.41
In vitro antimalarial activity of limonoids from Khaya grandifoliola C.D.C. (Meliaceae). J Ethnopharmacol (2000) 1.37
Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother (1998) 1.28
Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis (2000) 1.22
Analysis of the key pfcrt point mutation and in vitro and in vivo response to chloroquine in Yaoundé, Cameroon. J Infect Dis (2001) 1.20
In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon. Antimicrob Agents Chemother (1998) 1.20
Kinetics of lymphocyte subsets from peripheral blood during a Plasmodium falciparum malaria attack. Clin Exp Immunol (1992) 1.09
False chloroquine resistance in Africa. Lancet (1997) 1.06
Isotypic analysis of maternally transmitted Plasmodium falciparum-specific antibodies in Cameroon, and relationship with risk of P. falciparum infection. Clin Exp Immunol (1997) 1.06
Molecular epidemiology of malaria in Yaoundé, Cameroon. III. Analysis of chloroquine resistance and point mutations in the multidrug resistance 1 (pfmdr 1) gene of Plasmodium falciparum. Am J Trop Med Hyg (1998) 1.05
Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Am J Trop Med Hyg (2000) 1.03
Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. Trans R Soc Trop Med Hyg (2000) 1.02
[Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros]. Bull Soc Pathol Exot (2007) 1.01
Immune responses against Plasmodium falciparum asexual blood-stage antigens and disease susceptibility in Gabonese and Cameroonian children. Am J Trop Med Hyg (1999) 1.01
Immune response to Plasmodium falciparum antigens in Cameroonian primigravidae: evolution after delivery and during second pregnancy. Clin Exp Immunol (1997) 1.00
Site-based study on polymorphism of Plasmodium falciparum MSP-1 and MSP-2 genes in isolates from two villages in Central Africa. Parassitologia (2000) 1.00
Chloroquine-potentiating action of antihistaminics in Plasmodium falciparum in vitro. Ann Trop Med Parasitol (1991) 1.00
Malaria cellular immune responses in neonates from Cameroon. Parasite Immunol (1996) 0.99
[Surveillance of the in vivo sensitivity of Plasmodium falciparum to antimalarial agents: the results of initial tests of the OCEAC Malaria Network]. Med Trop (Mars) (1997) 0.92
Molecular epidemiology of malaria in Yaounde, Cameroon IV. Evolution of pyrimethamine resistance between 1994 and 1998. Am J Trop Med Hyg (1999) 0.92
Plasma levels of TNF-alpha soluble receptors correlate with outcome in human falciparum malaria. Eur Cytokine Netw (1994) 0.91
Molecular epidemiology of malaria in Yaounde, Cameroon. VII. Analysis of recrudescence and reinfection in patients with uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 0.91
Heterogeneity in the circumsporozoite protein gene of Plasmodium malariae isolates from sub-Saharan Africa. Mol Biochem Parasitol (1998) 0.90
Monitoring of the therapeutic efficacy of chloroquine for the treatment of uncomplicated, Plasmodium falciparum malaria in Iran. Ann Trop Med Parasitol (2006) 0.90
Molecular epidemiology of malaria in Yaounde, Cameroon. VIII. Multiple Plasmodium falciparum infections in symptomatic patients. Am J Trop Med Hyg (2001) 0.88
Relationships between malaria prevalence and malaria-related morbidity in school children from two villages in central Africa. Am J Trop Med Hyg (1999) 0.88
Diagnosis of Plasmodium malariae infection by the polymerase chain reaction. Trans R Soc Trop Med Hyg (1997) 0.88
[Plasmodium falciparum chemoresistance. The situation in Africa in 1989]. Med Trop (Mars) (1990) 0.88
In-vitro activity of primaquine against the asexual blood stages of Plasmodium falciparum. Ann Trop Med Parasitol (1999) 0.88
Type RI resistance to halofantrine in West Africa. Trop Med Parasitol (1991) 0.87
pfmdr1 gene mutation and clinical response to chloroquine in Yaoundé, Cameroon. Trans R Soc Trop Med Hyg (1997) 0.86
Molecular epidemiology of malaria in Yaounde, Cameroon I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg (1998) 0.85
Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg (2001) 0.85
Evolution of chloroquine resistance in central and west Africa. Trop Med Parasitol (1993) 0.84
Assessment of three in vitro tests and an in vivo test for chloroquine resistance in Plasmodium falciparum clinical isolates. J Clin Microbiol (1998) 0.84
[Drug-resistant malaria: problems with its definition and technical approaches]. Sante (2000) 0.83
[Stability of P. Falciparum resistance to chloroquine between 1987 and 1989 in Mounana, Gabon]. Bull World Health Organ (1992) 0.82
Assessment of pyronaridine activity in vivo and in vitro against the hepatic stages of malaria in laboratory mice. Trans R Soc Trop Med Hyg (2000) 0.82
Susceptibility of African isolates of Plasmodium falciparum to artemisinin (qinghaosu). Trop Med Parasitol (1992) 0.80
Resistant malaria in children. Indian Pediatr (2001) 0.80
Reduced in vitro susceptibility to halofantrine of Plasmodium falciparum in West Africa. Lancet (1990) 0.80
Evaluation of a new sulfadoxine sensitivity assay in vitro for field isolates of Plasmodium falciparum. Trans R Soc Trop Med Hyg (2001) 0.79
Chronotherapy of malaria: improved efficacy of timed chloroquine treatment of patients with Plasmodium falciparum infections. Trans R Soc Trop Med Hyg (1992) 0.79
Monitoring antimalarial drug efficacy. Clin Infect Dis (2004) 0.78
Chloroquine resistance in Plasmodium falciparum and polymorphism of the CG2 gene. J Infect Dis (1999) 0.78
Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: treatment failure and resistance in Malawi remain subject for debate. BMJ (2004) 0.77
[The role of nitric oxide in cerebral malaria]. Med Trop (Mars) (1995) 0.77
[Failure of chemoprevention with mefloquine in western Africa]. Presse Med (1990) 0.77
In vitro activity of cycloguanil against African isolates of Plasmodium falciparum. Antimicrob Agents Chemother (1993) 0.77
In vivo-in vitro test for chloroquine potentiation by cyproheptadine against Plasmodium falciparum. Trans R Soc Trop Med Hyg (1991) 0.76
Molecular epidemiology of malaria in Yaounde, Cameroon V. analysis of the omega repetitive region of the plasmodium falciparum CG2 gene and chloroquine resistance. Am J Trop Med Hyg (1999) 0.76
[Comparative study of artemether and quinine in severe Plasmodium falciparum malaria in adults and older children in Cameroon]. Med Trop (Mars) (1999) 0.76
Malarone-donation programme in Africa. Lancet (1998) 0.75
Point mutations in the Plasmodium falciparum cg2 gene, polymorphism of the kappa repeat region, and their relationship with chloroquine resistance. Trans R Soc Trop Med Hyg (2001) 0.75
Surveillance of antifolate-resistant malaria. Lancet (1998) 0.75
[Variability of in vitro activity of proguanil and cycloguanil on erythrocyte stages of Plasmodium falciparum as a function of culture conditions]. Bull Soc Pathol Exot (1999) 0.75
[A case of Plasmodium falciparum malaria contracted in Guinea-Bissau during chemoprophylaxis with chloroquine]. Presse Med (1990) 0.75
[Is there a revival of a focus of cutaneous leishmaniasis in Garoua, North Cameroon?]. Med Trop (Mars) (1994) 0.75
Efficacy of chloroquine-proguanil chemoprophylaxis against malaria in the Central African Republic. Trans R Soc Trop Med Hyg (1993) 0.75
[Severe malaria]. Rev Prat (1998) 0.75
[Severe chloroquine-resistant Plasmodium falciparum malaria acquired in Senegal]. Presse Med (1989) 0.75
[The cocaine body packer syndrome]. Presse Med (1986) 0.75
[Pulmonary tuberculosis and cutaneous anergy to tuberculin]. Rev Pneumol Clin (1987) 0.75
[Is gastroesophageal reflux responsible for the episodes of nocturnal desaturation in chronic bronchitis patients?]. Presse Med (1988) 0.75
Plasma levels of tumor necrosis factor (TNF) and neopterin during an attack of malaria. Ann Soc Belg Med Trop (1991) 0.75
Chloroquine self-treatment and clinical outcome of cerebral malaria in children. Clin Exp Immunol (1997) 0.75
Stabilization of chloroquine resistance in vivo of Plasmodium falciparum in Edea, south Cameroon. Trans R Soc Trop Med Hyg (1995) 0.75
[Mefloquine and halofantrine, new therapeutic drugs of malaria]. Rev Med Interne (1991) 0.75
Activity in vitro of chloroquine, cycloguanil, and mefloquine against African isolates of Plasmodium falciparum: presumptive evidence for chemoprophylactic efficacy in Central and West Africa. Trans R Soc Trop Med Hyg (1996) 0.75
[Epidemiological surveillance of Plasmodium falciparum sensitivity to chloroquine in Cameroon: necessity of public health policy adaptation]. Med Trop (Mars) (1995) 0.75
Antimicrobial resistance. Emerg Infect Dis (2001) 0.75